NCT01655719已完成2 期
Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 4
- 主要终点
- Tumor Response (Change)
研究概览
简要总结
Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimental.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically confirmed thyroid carcinoma with the PAX8-PPARgamma translocation (translocation testing will be performed on archived tissue during the screening period).
- •Refractory to radioactive iodine (RAI) as defined by: the tumor does not concentrate RAI; or the patient has had RAI within the last 16 months and has had progression despite that RAI; or the last RAI treatment was >16 months ago and the patient progressed after at least two RAI treatments; or the patient has received RAI treatments with a cumulative RAI dose of ≥22.2 GBq (600 mCi)
- •Not a candidate for surgery or RAI therapy with curative intent.
- •Lesions that would be treated by external beam radiation therapy (EBRT) based on standard of care can be so treated, but then cannot be used as target lesions.
- •Measurable disease by RECIST 1.1 criteria.
- •Documented disease progression by RECIST 1.1 in the past 14 months.
- •Availability of histological material (primary tumor or metastases) for review of the diagnosis and demonstration of PAX8-PPARgamma fusion gene.
- •Adequate TSH suppression (<0.5 mIU/L)
- •Prior chemotherapy or surgery must have been completed at least 28 days prior to registration, and all toxicities must have resolved.
- •Prior radioactive iodine must have been completed at least 6 months prior to registration, or there must be documented disease progression since such therapy if it was within 6 months. Sites that have received EBRT must have disease progression post-EBRT to be used as sites of measurable disease.
- •Life expectancy of greater than 6 months.
- •ECOG performance status 2 or less.
- •Patients must have normal organ function as defined below:
- •AST(SGOT)/ALT(SGPT) less than 2.5 X institutional upper limit of normal (within 1 month of study Day 1)
- •Patients must be able to consume oral medications.
- •Women of childbearing potential must have a negative pregnancy test at baseline prior to receiving any study drug and must practice effective contraception while on study. (Pregnant or lactating patients are excluded).
- •All patients must sign an informed consent prior to enrollment.
排除标准
- •Patients may not be receiving any other investigational agents.
- •Patients with known untreated brain metastases.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to pioglitazone.
- •Diagnosis of diabetes mellitus or current therapy with any drugs used to treat diabetes mellitus, including but not limited to insulin, sulfonylureas, metformin, rosiglitazone (Avandia), and pioglitazone (Actos) within 14 days of study Day 1
- •Therapy with rosiglitazone (Avandia) or pioglitazone (Actos) at any time since the diagnosis of thyroid cancer.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure, unstable angina pectoris, or cardiac arrhythmias.
- •Pregnant women are excluded from this study because pioglitazone is a U.S. Food and Drug Administration Pregnancy Category C drug. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pioglitazone, breastfeeding should be discontinued if the mother is treated with pioglitazone.
- •No concurrent radiotherapy or chemotherapy may be given to the patient during the administration of the study drug.
- •Patients with uncontrolled malabsorption syndromes.
- •Patients with a history of congestive heart failure of any New York Heart Association class.
- •Any medical or psychiatric illness which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment regimen.
- •Use of rifampin (strong CYP2C8 inducer) within 14 days of study Day
- •Other current malignancy than the disease under study.
- •Grade 2 or worse edema within 14 days of study Day 1, per CTCAE v4.
研究组 & 干预措施
Pioglitazone Treatment
Experimental
If eligible, subjects can participate in 1 or both parts of this study as follows:
Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.
Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment.
干预措施: Pioglitazone (Drug)
结局指标
主要结局
Tumor Response (Change)
时间窗: Baseline and 24 weeks
Response is measured by change in Tumor size (cm)
次要结局
- Toxicity(24 weeks)
- Change in Serum Thyroglobulin(Baseline and 24 weeks)
研究者
Ronald J. Koenig, MD PhD
Professor
University of Michigan
研究点 (4)
Loading locations...
相似试验
终止
早期 1 期
Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With GemcitabinePancreatic CancerNCT00867126University of Texas Southwestern Medical Center6
已完成
2 期
A Phase II Study of Pioglitazone for Patients With Cancer of the PancreasCancer of the PancreasNCT01838317University of Texas Southwestern Medical Center14
终止
2 期
Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung CancerStage IA Non-Small Cell Lung CarcinomaStage IB Non-Small Cell Lung CarcinomaStage IIA Non-Small Cell Lung CarcinomaStage IIB Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerNCT01342770National Cancer Institute (NCI)6
已完成
1 期
Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisNCT00919555Phoenix Neurological Associates, LTD28
撤回
2 期
Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat AsthmaAirway InflammationAirflow ObstructionAirway HyperactivityAsthmaNCT00604578National Heart, Lung, and Blood Institute (NHLBI)